BRAF and cancer: If the cancer type has known driver mutations, such as EGFR, BRAF, ERBB2 (HER2), ALK, etc., that were actionable and could be tested by single gene testing - and if so, was the patient treated with the targeted agent and became resistant to those therapies; 6.